肝细胞癌治疗的实验性和转化性研究进展
Advances in experimental and translational research in the treatment of hepatocellular carcinoma.
作者信息
Kidner Travis, Dai Menghua, Adusumilli Prasad S, Fong Yuman
机构信息
Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
出版信息
Surg Oncol Clin N Am. 2008 Apr;17(2):377-89, ix. doi: 10.1016/j.soc.2008.01.002.
Abstract
Hepatocellular cancer (HCC) is the fifth-leading cause of cancer and the third-leading cause of cancer related deaths world-wide. Current treatment options are limited, as HCC has been shown to be a highly resistant type of cancer to most current treatment modalities. Novel approaches are being explored in the fields of gene therapy, viral oncolytics, radioembolization, and several new biologic therapies. This article summarizes these recent clinical findings and discusses what role they will have in the future treatment of HCC.
摘要
肝细胞癌（HCC）是全球第五大致癌原因和第三大致癌相关死亡原因。目前的治疗选择有限，因为已证明HCC对大多数当前治疗方式具有高度抗性。基因治疗、溶瘤病毒、放射性栓塞和几种新的生物疗法等领域正在探索新的方法。本文总结了这些最新的临床发现，并讨论了它们在未来HCC治疗中将发挥的作用。
相似文献
1
Advances in experimental and translational research in the treatment of hepatocellular carcinoma.肝细胞癌治疗的实验性和转化性研究进展
Surg Oncol Clin N Am. 2008 Apr;17(2):377-89, ix. doi: 10.1016/j.soc.2008.01.002.
2
Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma.靶向腺相关病毒和腺病毒基因疗法治疗肝细胞癌
World J Gastroenterol. 2016 Jan 7;22(1):326-37. doi: 10.3748/wjg.v22.i1.326.
3
Gene therapy of liver cancer.肝癌的基因治疗。
World J Gastroenterol. 2006 Oct 14;12(38):6085-97. doi: 10.3748/wjg.v12.i38.6085.
4
Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.基于溶瘤病毒的肝细胞癌免疫疗法
Mediators Inflamm. 2017;2017:5198798. doi: 10.1155/2017/5198798. Epub 2017 Apr 20.
5
Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.不可切除肝细胞癌的治疗选择，重点是使用钇-90树脂微球的选择性内放射治疗（SIRT）
Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12972. Epub 2017 Jul 30.
6
Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.携带TRAIL和IL-12基因的溶瘤腺病毒联合治疗在体外和原位移植小鼠模型中均显著抑制人肝细胞癌。
J Exp Clin Cancer Res. 2016 May 6;35:74. doi: 10.1186/s13046-016-0353-8.
7
A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.一种新型高尔基体蛋白（GOLPH2）调控的溶瘤腺病毒在肝细胞癌中展现出强大的抗肿瘤功效。
Oncotarget. 2015 May 30;6(15):13564-78. doi: 10.18632/oncotarget.3769.
8
Localized hepatocellular carcinoma: therapeutic options.局限性肝细胞癌：治疗选择
Curr Gastroenterol Rep. 2000 Feb;2(1):72-81. doi: 10.1007/s11894-000-0054-4.
9
Perspectives of immunotherapy in hepatocellular carcinoma (HCC).肝细胞癌（HCC）免疫治疗的前景
Z Gastroenterol. 2016 Dec;54(12):1334-1342. doi: 10.1055/s-0042-120417. Epub 2016 Dec 9.
10
Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models.在患者来源的肝癌异种移植小鼠模型中，靶向热休克蛋白70（Hsp70）表达与细胞因子诱导的杀伤细胞（CIK）激活的免疫重建相结合可协同发挥抗肿瘤作用。
Oncotarget. 2015 Jan 20;6(2):1079-89. doi: 10.18632/oncotarget.2835.
引用本文的文献
1
Evaluation of miR-122-regulated suicide gene therapy for hepatocellular carcinoma in an orthotopic mouse model.miR-122 调控自杀基因治疗肝癌的原位小鼠模型评价。
Chin J Cancer Res. 2013 Dec;25(6):646-55. doi: 10.3978/j.issn.1000-9604.2013.11.07.
2
An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers.一种 N 端截短的羧肽酶 E 剪接异构体可诱导肿瘤生长，是预测人类癌症未来转移的生物标志物。
J Clin Invest. 2011 Mar;121(3):880-92. doi: 10.1172/JCI40433.
本文引用的文献
1
Advancements in hepatocellular carcinoma.肝细胞癌的进展
Curr Opin Gastroenterol. 2007 May;23(3):268-74. doi: 10.1097/MOG.0b013e3280ec5113.
2
p53 gene in treatment of hepatic carcinoma: status quo.p53基因在肝癌治疗中的现状
World J Gastroenterol. 2007 Feb 21;13(7):985-92. doi: 10.3748/wjg.v13.i7.985.
3
Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio.钇-90微球治疗原发性和转移性肝癌患者的安全性和有效性：治疗的肿瘤选择性与肿瘤-肝脏血流比的关系
J Transl Med. 2007 Mar 14;5:15. doi: 10.1186/1479-5876-5-15.
4
Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors.钇-90微球放射性栓塞：肝脏肿瘤新兴治疗方法综述
Future Oncol. 2007 Feb;3(1):73-81. doi: 10.2217/14796694.3.1.73.
5
Reversing hepatocellular carcinoma progression by using networked biological therapies.
Clin Cancer Res. 2007 Jan 1;13(1):11-7. doi: 10.1158/1078-0432.CCR-06-1619.
6
Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.感染细胞载体：癌症病毒疗法中溶瘤麻疹病毒全身递送的新策略。
Mol Ther. 2007 Jan;15(1):114-22. doi: 10.1038/sj.mt.6300020.
7
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.工程化麻疹病毒作为一种用于肝细胞癌的新型溶瘤病毒治疗系统。
Hepatology. 2006 Dec;44(6):1465-77. doi: 10.1002/hep.21437.
8
Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver.一项关于基因工程单纯疱疹病毒NV1020用于肝转移结直肠癌患者的I期开放标签剂量递增研究。
Hum Gene Ther. 2006 Dec;17(12):1214-24. doi: 10.1089/hum.2006.17.1214.
9
Gene therapy of liver cancer.肝癌的基因治疗。
World J Gastroenterol. 2006 Oct 14;12(38):6085-97. doi: 10.3748/wjg.v12.i38.6085.
10
Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial.尿嘧啶替加氟作为肝细胞癌辅助治疗药物的随机试验。
Hepatology. 2006 Oct;44(4):891-5. doi: 10.1002/hep.21341.
Zotero 插件